Author:
Freitas Cláudia,Sousa Catarina,Machado Francisco,Serino Mariana,Santos Vanessa,Cruz-Martins Natália,Teixeira Armando,Cunha António,Pereira Tania,Oliveira Hélder P.,Costa José Luís,Hespanhol Venceslau
Abstract
Liquid biopsy is an emerging technology with a potential role in the screening and early detection of lung cancer. Several liquid biopsy-derived biomarkers have been identified and are currently under ongoing investigation. In this article, we review the available data on the use of circulating biomarkers for the early detection of lung cancer, focusing on the circulating tumor cells, circulating cell-free DNA, circulating micro-RNAs, tumor-derived exosomes, and tumor-educated platelets, providing an overview of future potential applicability in the clinical practice. While several biomarkers have shown exciting results, diagnostic performance and clinical applicability is still limited. The combination of different biomarkers, as well as their combination with other diagnostic tools show great promise, although further research is still required to define and validate the role of liquid biopsies in clinical practice.
Reference215 articles.
1. Global Cancer Observatory;Int Agency Res Cancer,2020
2. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007;Walters;Thorax,2013
3. Cancer survival by stage at diagnosis for England (experimental statistics): Adults diagnosed 2012, 2013 and 2014 and followed up to 2015;Bannister;Off Natl Stat,2016
4. Liquid biopsy in early stage lung cancer;Pérez-Ramírez;Transl Lung Cancer Res,2016
5. The National Lung Screening Trial Research Team. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening;Aberle;N Engl J Med,2011
Cited by
51 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献